Business Wire

PURFI-GLOBAL

Share
PurFi Poised for Global Expansion of Circular Fiber Production Through Key Partnership with Concordia Textiles

PurFi, the U.S. developer of high-end products derived from rejuvenated textile waste streams, announces a joint venture with Belgium-based manufacturing partner Concordia Textiles. The new formation will be PurFi Manufacturing Belgium, headquartered in Waregem, Belgium, with management provided by Joy Nunn of PurFi and Carl Baekelandt of Concordia. The JV presents integration of ground-breaking sustainable textile technologies and enduring manufacturing practices in the creation of the first global circular fiber company with the ability to drastically minimize the irresponsible disposal of textile waste worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190806005824/en/

The partnership positions the company to realize a global reach with PurFi supplying exclusive circular fiber technologies which transform textile waste, regardless of composition, into fibers that are equal or superior in all aspects to virgin materials. In addition to fiber rejuvenation technologies, PurFi brings its state-of-the-art fiber lineage software which tracks fibers from their origins to their final destination. This technology provides a system of accountability throughout the entire process from downstream manufacturers to upstream retailers.

Integral to the proliferation of its technology on an international scale, Nunn recognized the need for a manufacturing partner with unique vision and ability.

“Carl and I recognized the importance of utilizing waste in manufacturing and the lack of that practice in the market. There aren’t any textile manufacturers making virgin quality products from textile waste without a [price] premium. On top of that, we shared a vision to take PurFi’s technologies and commercialize them at a global scale.”
- Joy Nunn, CEO PurFi

Concordia has the expertise to facilitate rapid global expansion. Founded in 1925, Concordia has nearly a century of expertise in textile manufacturing and finishing. As a completely vertically integrated textile manufacturer controlling the entire production flow from sizing and warp beaming over weaving, dyeing, printing, finishing, coating and laminating fabrics, the company is excited to be at the forefront of innovation and expand into sustainable fiber production.

“Some years ago, textiles made from recycled materials were just ‘nice to have’ in one’s product range. Today they are a must-have. More and more responsible brands commit themselves to using textiles made from rejuvenated fibers in their offering. Right from the start, Joy and I understood that combining the patented technology of PurFi with the Concordia Textiles Group’s extensive know-how of fabrics would enable us to contribute to textile upcycling on a global level. We consider the integration of circular economy principles in the strategy of our customers as one of the key pillars of our commitment to society.”
- Carl Baekelandt, CEO Concordia Textiles

With the globalization of these circular fiber technologies and their traceability, PurFi gives a high-end home, for a lower price, to fibers that would otherwise become shoddy or landfill. PurFi is dedicated to preserving resources, both natural and manmade, through sustainable technology and manufacturing practices.

Production is set to begin at the start of 2020 in Belgium.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release

- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc

Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse

Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release

IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the

HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 14:00:00 CEST | Press release

Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison

Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 13:45:00 CEST | Press release

Norwegian technology provider Cyviz has successfully developed a fully mobile and ballistic-proof command center - designed, configured, and made operational in just 24 hours. The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You do

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye